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Abstract
Background: The Death Receptor 6 (DR6) protein is elevated in the serum of ovarian cancer patients. We tested DR6 serum
protein levels as a diagnostic/predictive biomarker in several epithelial tumors and sarcomas.
Methods: DR6 gene expression profiles were screened in publically available arrays of solid tumors. A quantitative
immunofluorescent western blot analysis was developed to test the serum of healthy controls and patients with sarcoma,
uterine carcinosarcoma, bladder, liver, and pancreatic carcinomas. Change in DR6 serum levels was used to assay the ability
of DR6 to predict the response to therapy of sarcoma patients.
Results: DR6 mRNA is highly expressed in all tumor types assayed. Western blot analysis of serum DR6 protein
demonstrated high reproducibility (r = 0.97). Compared to healthy donor controls, DR6 serum levels were not elevated in
patients with uterine carcinosarcoma, bladder, liver, or pancreatic cancers. Serum DR6 protein levels from adult sarcoma
patients were significantly elevated (p,0.001). This was most evident for patients with synovial sarcoma. Change in serum
DR6 levels during therapy correlated with clinical benefit from therapy (sensitivity 75%, and positive predictive value 87%).
Conclusion: DR6 may be a clinically useful diagnostic and predictive serum biomarker for some adult sarcoma subtypes.
Impact: Diagnosis of sarcoma can be difficult and can lead to improper management of these cancers. DR6 serum protein
may be a tool to aid in the diagnosis of some sarcomatous tumors to improve treatment planning. For patients with
advanced disease, rising DR6 levels predict non-response to therapy and may expedite therapeutic decision making and
reduce reliance on radiologic imaging.
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Introduction
The death receptor (DR) proteins, a subset of the tumor necrosis
factor (TNF) receptors super-family, have been implicated as
serum biomarkers for solid tumors [1,2]. TNF receptor proteins
are present in tumor endothelial cells, tumor-associated myeloid
cells, and tumor cells with variable levels of expression. A primary
function for death receptors is to induce apoptosis [3]. Abnormal
expression, regulation, or function of TNF receptors have been
strongly implicated in autoimmune disease, osteoporosis, and
cancer [4,5,6,7,8,9,10]. Six different death receptors are currently
known.
The most recently identified TNF receptor is Tumor Necrosis
Factor Receptor Superfamily Member 21 (TNFRSF21), also
known as death receptor-6 (DR6). The function of DR6 in cancer
is not entirely clear [11]. DR6 retains the characteristics of other
family members, including a cysteine-rich extracellular domain
and conserved intracellular death domain required for induction
of cell death. Thus, like other death receptor proteins, DR6 has
been implicated in the induction of apoptosis [12]. Additionally,
DR6 may regulate the cytokine-driven differentiation of mono-
cytes to dendritic cells, which suggests DR6 could play a role in the
development of myeloid derived suppressor cells within tumors
[11].
We recently identified DR6 as a potential serum tumor marker
in ovarian cancer [1]. In addition to its expression in ovarian
cancer, DR6 has been reported to be up-regulated in numerous
solid tumors [13]. DR6 is expressed not only in cancer cells, but
also in tumor vascular cells. This expression on host cells in the
tumor microenvironment suggests DR6 may have broad applica-
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bility as a tumor biomarker. The role of DR6 as a biomarker in
non-ovarian tumors has not heretofore been investigated.
We report here an analysis of DR6 as a potential biomarker in
several non-ovarian tumors. In particular we analyzed the role of
DR6 as a potential serum biomarker in adult sarcoma. Sarcomas
in the adult are rare but relatively deadly. Unlike other
malignancies, there are no clinically used serum biomarkers to
suggest a potential mass may represent sarcoma. Similarly, there
are no serum biomarkers which can be used with confidence to
predict whether a patient receiving therapy is or is not gaining
clinical benefit. Our studies suggest that serum DR6 levels are
elevated in patients with some sarcomas. In addition, declining
DR6 levels may identify those patients gaining clinical benefit
from systemic therapy.
Materials and Methods
Gene Expression
We screened the gene expression profile of numerous tumor
types using publically available array data [14,15]. OncomineTM
(Compendia Bioscience, Ann Arbor, MI) was used for analysis and
visualization. Data sets were analyzed independently and then
combined with the normalized log 2 median centered intensity of
zero.
Tumor tissues were obtained using IRB approved tumor
banking protocols at the University of Michigan and the
Cooperative Human Tissue Network. Tissues included normal
colon (n = 3), normal liver (n = 2), normal ovary (n = 5), bladder
cancer (n = 2), breast cancer (n = 5), carcinosarcoma (n = 3),
Figure 1. DR6 mRNA expression. Expression of DR6 mRNA in cancer expression arrays. A. DR6 mRNA expression in microarrays of the indicated
tumor types determined using OncomineTM software. Thick lines indicate the median, thin lines indicate the 90th/10th percentiles, box indicates 25th–
75th percentiles, dots indicate the minimum and the maximum. B. Quantitative PCR confirming DR6 mRNA expression levels in the indicated tumor
types. Average expression with standard error are indicated (n = 2–5 tumors in each group).
doi:10.1371/journal.pone.0036525.g001
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hepatic cancer (n = 2), ovarian cancer (n = 5), pancreatic cancer
(n = 3), and soft tissue sarcoma (n = 3 leiomyosarcoma, n = 2
uterine sarcoma). RNA was extracted from fresh frozen tissues
using TRIzol per manufacturer’s recommendations (Invitrogen,
Grand Island NY) and qRT-PCR was then performed as
previously described [1].
Patients
Written informed consent was obtained from all patients prior
to sample collection. Protocols for serum collection were reviewed
and approved by the University of Michigan Institutional Review
Board or the University of New Mexico Institutional Review
Board (IRB). All clinical investigation was conducted according to
the principles expressed in the Declaration of Helsinki. Five
milliliters of blood was collected by venipuncture directly into
serum separator tubes, centrifuged at 3000 RPM for 12 minutes,
and then aliquoted into polypropylene vials and frozen at 270
degrees Celsius until use. Sera from patients with either
carcinosarcomas or cancers of the bladder, liver, or pancreas
were collected preoperatively as part of IRB approved University
of Michigan serum banking protocols.
Serum from patients with sarcoma was available from a total of
71 patients participating in IRB approved clinical trials. Serum
was obtained from all 71 patients prior to trial initiation. 22 of
these patients were participating in a therapeutic clinical trial at
the University of New Mexico for chemotherapy-naı¨ve patients.
This serum was collected prior to initiation of either neo-adjuvant
therapy or salvage therapy for metastatic disease. 49 of the patients
were participating in a phase II clinical study of cyclophosphamide
and sirolimus in patients with previously treated advanced adult
sarcoma. A second sample was obtained from 41 patients at the
University of Michigan after one cycle of therapy; two of these
patients later donated a third sample after completing two cycles of
therapy. Patients on trial were evaluated for progression via
Figure 2. Development of a quantitative western blot assay for DR6. A. Representative quantitative immunofluorescent western blot
analysis of DR6 serum protein expression from ovarian cancer patients and donor control patients. B. Concordance of western blot analysis of
replicate samples in independent experiments (r = 0.97). C. Concordance of inter-day (gray) and intra-day (black) replicates of reference serum
standards. D. Serum protein levels from control and patients with the indicated cancer types. Only adult sarcoma patients demonstrated a statistically
significant increased expression of serum DR6 protein compared to control.
doi:10.1371/journal.pone.0036525.g002
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radiographic imaging every 2 months. Finally, control serum was
collected as part of an IRB approved protocol, primarily from
healthy volunteers age 18–65. Approximately 20% of control sera
were collected preoperatively from patients who were ultimately
diagnosed with benign ovarian conditions, including fibroade-
noma, benign follicular cysts, cystadenomas, and endometriotic
cysts.
Immunofluorescent western blot
A ‘master scale’ was developed with duplicate serial dilutions
(0.25, 0.5, 1, 2, and 4 ul) of a single healthy control sera (GS)
diluted into 40 ml PBS and then 15 ml of diluted serum was loaded
with 5 ml of 26 loading buffer for PAGE. Immunofluorescent
detection was performed using anti human DR6/TNFRSF21
affinity purified polyclonal goat IgG (1:500, R&D Systems,
Minneapolis, MN). Primary was detected with fluorescent donkey
infrared dye 800CW conjugated anti-goat IgG (1:5000 LiCor
Biosciences, Lincoln NE). After washing, fluorescent images were
captured with the Odyssey SA Infrared Imaging System (LiCor
Biosciences) and quantified with LI-COR Odyssey Software
version 2.1 per the manufacturer’s instructions (http://
biosupport.licor.com/docs/Odyssey_User_Guide_ver_3.0B.pdf).
Captured digital images were quantified with using same size
rectangle method to determine the integrated intensity value (pixel
volume). Background values were subtracted from each experi-
mental sample. Immunofluorescent western blot was run in
duplicate for each and expression values indicated are averages
of the two samples. Best linear fit was determined for the master
scale using Microsoft XL. For each subsequent gel, experimental
samples were run in a similar manner with 1 ml diluted into 40 ml
of PBS, and a mini internal control sera scale (0.5, 1.0 and 2.0 ml)
of GS sera was included for relative quantification. A normalized
value was determined for each sample based in the internal control
sample. The normalized value was then used in the linear
correlation of the master gel to determine the relative expression
value. Any samples with raw values outside the linear range of the
assay (2000–25,000 expression units) were re-analyzed with
additional dilutions. Dilution factor was taken into account after
normalization.
Statistical analysis
Descriptive statistics for serum concentrations of DR6 were
calculated for each subject using GraphPad Prism5 software
(GraphPad Software, Inc., La Jolla, Ca.). Unpaired t-tests were
used with the minimum level of significance taken as p,0.05.
Logistic regression analysis was used to estimate the association
between the DR6 serum levels and case status (sarcoma patients
versus controls). The receiver operating characteristic (ROC)
curve was computed for DR6 to evaluate it as a diagnostic
biomarker and the area under the curve (AUC) was computed.
Proc Logistic was used for this analysis (SAS Software, version 9.2,
Cary, NC.).
Results
Death Receptor 6 gene expression and protein serum
levels across various tumor types
In an attempt to identify tumors with high DR6 expression, we
screened the gene expression profile of numerous tumor types
using publicly available array data [14,15]. DR6 expression was
detectable in all tumor types, with the highest expression noted in
bladder, pancreatic, and squamous cell lung cancers (Figure 1A).
We next performed quantitative PCR for DR6 using cDNA from
normal ovary, colon, and liver tissues and well as cDNA obtained
from a panel of whole tumor samples. qRT-PCR confirmed
increased DR6 mRNA levels in these tumors relative to the
normal tissue controls, with the highest expression detected in
bladder cancer, pancreatic cancer, hepatic cancer and adult
sarcomas (Figure 1B).
We next developed a quantitative immunofluorescent western
blot analysis approach to analyze DR6 protein levels. We used
serum samples from ovarian cancer patients for which DR6 had
previously been demonstrated to be elevated. Ovarian cancer
serum samples were analyzed in duplicate together with internal
standards to allow comparison between experiments. Analysis of
duplicate samples within the same and different experiments
revealed this method to be highly reproducible (R = 0.97,
Figure 2A and B). Analysis of a minimum of 7 intra-day and 7
inter-day samples revealed a high degree of reproducibility
(Figure 2C and Table 1). In addition, we found that up to 8
cycles of serum freezing/thawing had no impact on DR6 levels
(data not shown).
Once the assay was confirmed, we screened DR6 serum protein
levels from a panel healthy donor controls and a panel of patients
with different tumor types including bladder cancer, hepatic
cancer, pancreatic cancer, mullerian carcinosarcomas, and adult
sarcomas. Interestingly, while qRT-PCR data demonstrated the
highest DR6 mRNA levels in bladder cancer, pancreatic cancer,
hepatic cancer and adult sarcomas, serum DR6 protein levels were
statistically significantly elevated only in the serum of patients with
adult sarcomas (Figure 2D). None of the other tumor types
demonstrated a statistically significant increase in serum DR6
protein levels relative to healthy controls.
DR6 serum protein level in patients with sarcoma versus
control
Based on the preliminary screen above, serum DR6 levels were
then compared using a panel from 71 adult sarcoma patients and
39 healthy controls. Table 2 summarizes the patient character-
istics. 22 patients were chemotherapy naı¨ve, with 10 of these
patients receiving neo-adjuvant therapy for localized disease; the
remaining 12 patients had metastatic disease. 49 patients had
metastatic chemo-refractory disease, having received an average of
3 previous lines of chemotherapy. We observed a 2.2 fold increase
Table 1. Statistical analysis of fluorescent western blot assay
replicates.
Serum Dilution 1:6 1:2 1:1
Number of times assayed 18 36 14
Minimum 3130 11752 26411
25% Percentile 4165 13831 29478
Median 5183 14832 30044
75% Percentile 6119 15694 31214
Maximum 7688 17657 41317
Mean 5177 14701 30616
Standard Deviation 1299 1517 3394
Standard Error 306.3 252.8 907.1
Lower 95% Confidence Interval of mean 4531 14187 28656
Upper 95% Confidence Interval of mean 5823 15214 32575
doi:10.1371/journal.pone.0036525.t001
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in DR6 levels relative to normal controls (controls 0–15376
integrated intensity units, all sarcoma 4289–34298 integrated
intensity units). More than 40% of sarcoma samples were found to
be higher than the maximum expression in the normal control set
(Figure 3A). Similar results were found for both chemo-naı¨ve and
chemo-refractory patients (Figure 3B). The association between
case status (sarcoma patient versus control) and DR6 was statically
significant (odds ratio = 1.3, 95% CI = 1.17 to 1.46, p,0.001).
There was a 1.3-fold increase in the odds that a patient was
a sarcoma patient for the group of patients with a 10,000 unit
increase in DR6 compared to the odds for those at the base level.
In addition, when DR6 was evaluated as a diagnostic marker with
its ROC curve, the AUC was 82.1% (Figure 3C).
We further evaluated DR6 expression based on histologic
subtypes, including myogenic sarcoma (22 leiomyosarcoma and 2
rhabdomyosarcoma), liposarcoma (n = 11), bone sarcoma (4
osteosarcomas and 1 Ewing sarcoma), peripheral nerve sheath
tumor (n = 4), synovial sarcoma (n = 6), angiosarcoma (n = 5), and
undifferentiated sarcoma (5 pleomorphic undifferentiated, 3
undifferentiated uterine, 6 undifferentiated-NOS, and 3 extra-
skeletal myxoid chondrosarcomas) (Figure 3D). All groups, except
angiosarcoma (p value = 0.386), retained a highly significant
Figure 3. Sarcoma patients have significant elevation of DR6 serum protein. A. DR6 protein expression in a panel of 39 healthy controls
and 71 patients with adult sarcoma. B DR6 levels in healthy controls and in sarcoma patients separated into chemo-naı¨ve and chemo-refractory sub-
groups. C. Receiver operator characteristic (ROC) curve for DR6 serum level in sarcoma patients versus controls. Area under the curve is 82.1%. D.
Sarcoma patient DR6 serum protein levels based on histologic subtype. Averages are indicated by a long horizontal line. Brackets indicate standard
deviations.
doi:10.1371/journal.pone.0036525.g003
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increase of serum DR6 compared to normal controls (p
values,.0001–0.0044). The greatest difference among all subsets
was seen in synovial sarcoma, which showed a 3.1 fold increase
over normal controls. Bone sarcoma had the second greatest
elevation (2.3 fold) followed by undifferentiated sarcoma (2.1 fold
increase), liposarcoma (2.0 fold increase), and peripheral nerve
sheath tumor and myogenic sarcoma, which both increased 1.9
fold.
The role of DR6 in predicting disease progression
Clinical disease response information with pretreatment and on-
treatment serum samples was available for 41 sarcoma patients.
We next evaluated whether the change in DR6 levels before and
after treatment correlated with disease response or clinical benefit.
Thirty-nine patients had sera obtained pre-treatment and after 1
cycle of therapy, and 2 patients had an additional serum samples
obtained after a second cycle. 12 of 41 patients demonstrated
stable disease after 4 cycles (4 months) of therapy. Importantly, of
the twelve patients with stable disease on therapy, 9 demonstrated
a decrease in their DR6 levels (sensitivity = 75%, Figure 4A). 18 of
21 patients with increasing Dr6 levels demonstrated progressive
disease within 2 months of starting treatment (positive predictive
value = 85.7%). The negative predictive value and specificity were
45% and 62.1% respectively (Figure 4B). Similar results were
obtained if samples which demonstrated ,10% change in DR6
levels were considered as ‘stable disease’.
The only histological subtypes for which we had more than
n = 4 samples in which to evaluate change in DR6 level in
response to therapy were leiomyosarcoma (n = 18) and liposar-
coma (n = 6). For leiomyosarcoma, change in DR6 serum protein
after the first cycle of therapy did not appear to be a useful
predictive biomarker (Fig. 4C(1)). For liposarcoma change in DR6
serum protein level after one cycle of therapy demonstrated 100%
sensitivity and specificity to predict stable disease versus pro-
gressive disease (Fig. 4C(2)). Caution must be taken in interpreting
this data given the small sample size.
Discussion
Adult sarcoma is a rare but relatively deadly cancer [16]. The
World Health Organization (WHO) describes more than 50
histological subtypes of soft tissue sarcomas associated with unique
clinical features and biologic behavior [17]. Because of their rarity
and diversity of presentation, sarcomas can be difficult to diagnose.
This is so mainly because benign soft tissue masses outnumber
sarcomas by a factor of at least 100 [17]. In the present study, we
demonstrated that compared to healthy controls, adult patients
with sarcoma have increased serum DR6 protein levels (p,0.001).
We observed this in two independently collected sera banks. As
a biomarker of sarcoma, DR6 could help to differentiate sarcomas
from benign soft tissue masses. This would aid in appropriate
surgical treatment planning, which is imperative because appro-
priate surgical management is associated with improved outcome
[18–19]. Additional confirmatory studies are necessary.
Given the heterogeneity of sarcomas it seems unlikely that any
tumor marker would be equally informative in all histologic
subtypes. As a diagnostic tool, DR6 appears to have greatest
potential in patients with synovial sarcoma; the lowest DR6 serum
level in patients with synovial sarcoma measured well above that of
all controls. Similarly, change in DR6 serum protein levels may
serve as a predictive biomarker for some patients receiving
chemotherapy. This potential appears greatest for patients with
liposarcoma. However, given the small sample size in our study,
prospective studies will be necessary to confirm this observation.
Our analysis of DR6 as a predictive biomarker is limited by the
fact that only two time points were collected during therapy; at
pre-treatment and before the second cycle of therapy. Biomarker
‘surge’, the initial spike of a marker measured following a cycle of
effective treatment, could confound results when evaluating values
of only two early, short-interval time points. Analysis of DR6 trend
from pretreatment to later cycles of therapy could be more
informative [20]. In fact, in our study two patients did provide
serum for analysis prior to the third cycle of systemic therapy. One
patient had progressive disease with a slight decrease in DR6 at
the second visit; however, there was a dramatic increase in DR6
with the third serum sample. Another patient had stable disease
with four cycles of therapy and showed an increase in DR6 after
the first cycle of therapy, but then showed a precipitous decline
after the second cycle. Further studies with serial evaluation of
DR6 as a biomarker of response in the setting of standard sarcoma
chemotherapy are necessary. Finally, if this is to be developed as
a clinical assay, an ELISA assay that can easily be used for bulk
testing would be beneficial. Unfortunately, we have found the
currently available antibodies unsuitable for ELISA. While many
of these antibodies work with denatured DR6 on western blot, or
with ELISA for bacterially produced DR6 fusion proteins, we
found that the currently available antibodies were not successful in
recognizing native DR6 in patient serum. Ultimately, new
antibodies will be necessary to recognize native DR6.
Surprisingly, DR6 protein in sera did not correlate with mRNA
expression levels in tumors (data not shown). Thus DR6 serum
protein level may not be regulated at the level of mRNA.
Consistent with this, it was recently shown that soluble DR6 is the
result of matrix metalloproteinase 14 (MMP-14) cleavage of
membrane bound DR6 [21]. Thus serum DR6 protein may serve
as an indicator of tumor MMP-14 levels. MMP-14 has been
Table 2. Characteristics of Sarcoma Patients Evaluated.
Chemo-
refractory Chemo-Naive
Median Age – years (range) 57 (19–82) 54 (17–75)
Male/Female 28/21 13/9
Median prior lines of
chemotherapy
3 NA
(range) (1–6)
Stage II/III/IV NA 2/7/13
Sarcoma sub-type
Leiomyosarcoma 16 6
Liposarcoma 9 2
Undifferentiated Pleiomorphic 5 0
Osteosarcoma 4 0
Synovial sarcoma 3 3
Peripheral nerve sheath tumor 3 1
Rhabdomyosarcoma 2 0
Extraskeletal myxoid
chondrosarcoma
2 1
Angiosarcoma 1 3
Undifferentiated NOS/Other 4 6
Neoadjuvant/Metastatic 0/49 10/12
NA-not applicable.
doi:10.1371/journal.pone.0036525.t002
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Figure 4. Correlating change in DR6 serum protein over time with response to therapy. A. Waterfall plot of change in DR6 serum protein
values prior to and after therapy with sirolimus and cyclophosphamide in patients with advanced sarcoma; patients with stable disease are indicated
by black bars and patients with progressive disease are indicated in Gray. B. Sensitivity, specificity, negative predictive value (NPV) and positive
predictive value (PPV) for the change in DR6 serum protein levels to predict stable disease versus disease progression in sarcoma patients on therapy.
C. Waterfall plot of change in DR6 serum protein values prior to and after therapy with sirolimus and cyclophosphamide in patients with (1)
leiomyosarcoma and (2) liposarcoma. Patients with stable disease are indicated by black bars and patients with progressive disease are indicated in
Gray.
doi:10.1371/journal.pone.0036525.g004
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correlated with tumor invasion, metastases, and poor patient
prognosis [22].
Summary
DR6 serum protein levels demonstrate a 2–3 fold increase in
patients with sarcoma, relative to normal healthy controls. A
retrospective analysis of DR6 serum protein levels suggests that
DR6 may be a biomarker for disease progression in patients with
sarcoma. These studies support prospective evaluation of DR6 as
a predictive biomarker in sarcoma patients undergoing treatment
with standard chemotherapy.
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